Modification of the peptides during and post synthesis to meet user requirements:
Synthesis of peptides at various different scales (100 mg to grams) and Purification and characterisation using HPCL and HPLC -MS .
Scientific and technical support and advice on immunogen design, immunoreagent synthesis and production, antibody production and immunoassay design and development.
Nanosight NS300; Malvern Instruments
Descripción: Automated analysis of the size distribution and concentration
The Malvern NanoSight NS300 uses the technology of Nanoparticle Tracking Analysis (NTA). This unique technology utilizes the properties of both light scattering and Brownian motion in order to obtain the size distribution and concentration measurement of particles in liquid suspension. A laser beam is passed through the sample chamber, and the particles in suspension in the path of this beam scatter light in such a manner that they can easily be visualized via 20x magnification microscope onto which is mounted a camera. The camera operates at 30 frames per second (fps), capturing a video file of the particles moving under Brownian motion. The software tracks many particles individually and using the Stokes-Einstein equation calculates their hydrodynamic diameters.
Location: Laboratory SCF. (MATGAS)
More info: http://www.malvern.com/en/products/product-range/nanosight-range/nanosight-ns300/default.aspx
Especificaciones técnicas:
Wavelength: 405nm (violet), 488nm (blue), 532nm (green) or 642nm (red).
Temperature control range: 5°C below ambient to 55°C.
Stage: Fixed stage.
Focus: Computer controlled motorized focus.
Camera:
Fluorescence: Motorized 6 place filter wheel with choice of filters.
Particle size: 10nm to 2000nm.
Concentration range: 106to 109 particles per mL.
Quantitative studies of biomolecular interactions by calorimetric measurements.
Detection of labeled nanoparticles and exosomes by fluorescence mode.
Cardiac electrophysiology lab with navigation (CARTO 3) and biotherapeutics delivery (NOGA XP) systems.
e.g. Course on “Strategies for optimization of recombinant protein production”)
Researchers from the Folding and Conformational Diseases Group at the Institute of Biotechnology and Biomedicine Group are part of the European project Neuromed to develop molecules and detect biomarkers of this disease before the signs of neurodegeneration become evident.
The Neuromed project is led by the University of Zaragoza and aims to design molecules, drugs and new diagnostic tools early for three neurodegenerative diseases in which defective proteins are involved: Parkinson’s disease and two rare diseases, phenylketonuria and protein TTR Amyloidosis.
The coordination of the Parkinson’s research line will be directed, from the IBB, by Salvador Ventura, principal researcher and director the Protein Folding and Conformational Diseases group and Professor at the Department of Biochemistry and Molecular Biology at the UAB. Researchers in his group are also involved in the project.
The goal of Professor Ventura and his collaborators is focused on developing a diagnostic kit that will allow early and sensitive detection of the presence of Parkinson’s biomarkers in blood and cerebrospinal fluid, in such a way that the treatment of the disease can begin before the signs of neurodegeneration are obvious.
Neuromed strikes a common element of the three diseases to be investigated: their conformational defects. The research will look for new molecules that can even recover the activity of defective proteins. The combination of computational and biophysical techniques to identify and develop compounds that are tested in cell and animal models would allow the development of drugs active on the three diseases, and will contribute to the early diagnosis of Parkinson.
The Consortium Neuromed involves six partners from Spain, Portugal and France. The research groups, Including the one of professor Ventura, have consolidated expertise in the approach to diagnose and treat these diseases. The project will run for 14 months and has a total cost exceeding EUR 1 million.
